Daniel J. Thomas

About Daniel J. Thomas

Independent director and Lead Director of Concentra Group Holdings Parent, Inc. (CON). Age 66; director since 2024; designated Lead Director in 2024. Former CEO/President/COO of Concentra predecessor OccuSystems/Concentra (1993–2007), CEO of Viant, CEO of Provista (2011–2017), and President/CEO of National Partners in Healthcare (2018–2019). Determined independent under NYSE rules; serves as Audit Committee financial expert and chairs the Audit & Compliance Committee .

Past Roles

Organization	Role	Tenure	Committees/Impact
Concentra/OccuSystems (predecessor)	President, CEO, COO	1993–2007	Led growth to national scale; sale to Humana in 2010 highlighted track record
Viant, Inc.	CEO, Director	Prior to 2011	Executive leadership in provider/payer/supply chain services
Provista, Inc.	President, CEO, Director	2011–2017	Supply chain and GPO experience
National Partners in Healthcare	President & CEO	Jun 2018–Jan 2019	Short-term turnaround leadership

External Roles

Organization	Role	Tenure	Notes
Select Medical Holdings Corporation	Director	Since Jul 2019	Public company board; CON’s former parent (spinoff Nov 2024)
National Partners in Healthcare	Director	Current	Private company board
Revelohealth	Director	Current	Private company board
Equalis Group LLC	Director	Current	Private company board
Healthcare Highways, Inc.	Director	Prior	Former board role
Accentcare, Inc.	Director	Prior	Former board role

Board Governance

Roles: Lead Director; Audit & Compliance Committee Chair; member, Human Capital & Compensation Committee .
Independence: Board determined Thomas is independent under NYSE standards; Board currently majority independent .
Audit expertise: Designated “audit committee financial expert” under Item 407(d)(5) of Regulation S‑K; Audit Committee meets requirements and is phasing to full independence post-IPO .
Attendance/engagement: Board met twice in FY2024; all directors attended all Board and committee meetings of which they were members; independent directors hold regular executive sessions presided by Lead Director .
Tenure/class: Class I director; nominated for re-election; term expires 2025 (election for term through 2028) .
Director ownership guidelines: Required to hold stock valued at ≥5× annual cash compensation (excluding meeting fees); 3-year compliance window from appointment .

Fixed Compensation

Component	Amount/Policy	Notes
Quarterly cash retainer (non-employee directors)	$12,500 per quarter	Standard cash compensation
Board meeting fee (in-person)	$3,000 per meeting	Telephonic: $600 per meeting
Audit & Compliance Committee meeting (in-person)	$3,000 ($4,000 if independent of Board meeting)	Telephonic: $1,500; Chair add’l: $1,000 in-person; $500 telephonic
Quality of Care & Patient Safety Committee meeting (in-person)	$2,000 ($3,000 if independent of Board meeting)	Telephonic: $1,000; Chair add’l: $1,000 in-person; $500 telephonic
All other committees (in-person)	$1,000 ($2,000 if independent of Board meeting)	Telephonic: $500; no chair add’l
Thomas – Fees Earned (2024)	$44,103	As reported; reflects actual attendance/roles

Performance Compensation

Grant Type	Grant Date	Shares	Grant Date Fair Value	Vesting Terms	Performance Metrics
Restricted Stock (Director grant)	Nov 26, 2024	12,992	$299,985	50% vests pro rata annually over 5 years (onboarding grant); 50% vests at first anniversary (annual grant)	None; time-based vesting only

No director PSUs or option awards disclosed for 2024; time-based RSAs only (no TSR/EBITDA/ESG metrics for director pay) .

Other Directorships & Interlocks

Public interlock: Director at Select Medical Holdings while CON executed a separation and distribution from Select in 2024; Select no longer a related party post-distribution, but a Transition Services Agreement exists with cash compensation waived by Select’s Executive Chairman for CON board service during TSA term .
Private boards: National Partners in Healthcare, Revelohealth, Equalis Group LLC; prior Healthcare Highways and Accentcare .

Expertise & Qualifications

Healthcare operator and payer/provider services expertise across 30+ years; led Concentra’s national growth to ~$1.3B revenue and subsequent sale to Humana .
Financial oversight: Audit committee financial expert; familiarity with cybersecurity, compliance, ERM oversight through Audit & Compliance charter .
Lead Director responsibilities include agenda setting, presiding over executive sessions, shareholder liaison, and convening independent director meetings .

Equity Ownership

Holder	Shares Beneficially Owned	Percent Outstanding	Unvested Director RSAs (12/31/2024)
Daniel J. Thomas	66,252	<1%	12,992

Director stock ownership guideline: ≥5× annual cash compensation (excluding meeting fees); 3-year period to meet guideline from appointment .

Governance Assessment

Strengths:
- Independent Lead Director and Audit Chair with designated audit committee financial expert status; strong attendance and engagement; Board majority independent; regular executive sessions .
- Clear director stock ownership guidelines; anti-hedging and clawback policies applicable broadly in governance framework .
Watch items / RED FLAGS:
- Compensation Committee not yet fully independent during NYSE phase-in, includes Executive Chairman (Ortenzio); Thomas previously an employee of CON (1993–2007), noted in “interlocks and insider participation,” which may raise perceived independence sensitivities despite formal independence .
- Public interlock with Select’s board while CON maintains transition/separation agreements; although Select is no longer a related party post-distribution, oversight of any continuing arrangements warrants monitoring for conflict management and recusal practices .
Alignment:
- Director equity grant structure is time-based, promoting retention and alignment; Thomas’s 2024 mix is predominantly equity (cash $44,103 vs equity fair value $299,985) .
Attendance signal:
- 100% attendance at Board and applicable committees in 2024 indicates strong engagement .